# Phase 1 First-in-human Study of JS014

> **NCT05296772** · PHASE1 · UNKNOWN · sponsor: **Anwita Biosciences** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasm Malignant
- Neoplasm, Experimental
- Solid Tumor, Adult
- Lymphoma

## Interventions

- **BIOLOGICAL:** JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
- **BIOLOGICAL:** Pembrolizumab - anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT05296772
- **Lead sponsor:** Anwita Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-28
- **Primary completion:** 2024-06
- **Final completion:** 2025-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296772, "Phase 1 First-in-human Study of JS014". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05296772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*